AcuCort will participate in three investor presentations during March. CEO Jonas Jönmark will summarize the latest news and discuss the launch of the oral film Zeqmelit®.
What does the process look like regarding the launch of the oral film Zeqmelit® and how will the company evolve with the transition from a research company to a pharmaceutical company? These are the key areas that will be addressed when AcuCort’s CEO Jonas Jönmark participates in Stora Aktiedagen, Invest Live, and Stockholm Corporate Finance Capital Markets Days Life Science in the near future.
Information about the presentations:
- Stora Aktiedagen: March 5th, at 09:15
- Invest Live: March 12th, at 14:00
- Stockholm Corporate Finance Capital Markets Days Life Science 2024: March 12th, in the morning.
Invest Live is a digital event produced by Investor Target IR & Capital, Stockpicker, and Direkt Studios. The event is broadcast live on YouTube: https://www.youtube.com/watch?v=dloendYixe4
Stora Aktiedagarna is a hybrid event organized by Aktiespararna. The event is broadcast live on www.aktiespararna.se
Stockholm Corporate Finance Capital Markets Days Life Science 2024 is a hybrid event broadcast live at: https://www.lyyti.fi/reg/Stockholm_Corporate_Finance_Life_Science
For further information:
Jonas Jönmark, CEO AcuCort AB
Tel: +46 70 3655400
Email: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.